The abortion pill Supreme Court ruling came down on June 13, 2024, when all nine justices unanimously dismissed the challenge to mifepristone in FDA v. Alliance for Hippocratic Medicine. The Court did not decide whether the FDA acted lawfully when it loosened restrictions on the drug. It decided only that the doctors and medical organizations who sued had no legal right to bring the case, because they could not show the FDA’s rules had personally injured them. Mifepristone’s current rules — including telehealth prescriptions and mail delivery — stay in place. The underlying legal questions do not.
What the Court Actually Decided
Justice Brett Kavanaugh’s opinion never reached the FDA’s science, its procedures, or the merits of the 2016 and 2021 rule changes the plaintiffs wanted overturned. The opinion turned on Article III standing: federal courts can only hear cases brought by someone who has suffered a real, concrete injury caused by the defendant’s conduct.1Constitution Annotated. ArtIII.S2.C1.6.1 Overview of Standing The plaintiff doctors did not clear that bar.
Kavanaugh stated the core problem plainly: the plaintiffs do not prescribe or use mifepristone, and the FDA is not requiring them to do or refrain from doing anything. Their real goal was to make the drug harder for other doctors to prescribe and for other people to obtain, and wanting to restrict someone else’s access to a product does not create a legal right to sue.2Supreme Court of the United States. Food and Drug Administration et al. v. Alliance for Hippocratic Medicine et al. The opinion acknowledged this might mean no private party has standing to bring this kind of challenge, and said flatly that this is not a reason to manufacture standing. Some disputes belong in the political process rather than the courts.
Why Both Injury Theories Failed
The Alliance for Hippocratic Medicine offered two theories of harm. The Court rejected both.
The first was a conscience injury. Plaintiffs argued that looser FDA rules would produce more complications, that some of those patients would end up in emergency rooms where the plaintiff doctors work, and that the doctors would then be forced to provide care that violated their moral beliefs. The Court found this chain of events too speculative to count as injury. Federal law also already addresses the concern. The Church Amendment, on the books since 1973, says that receiving federal healthcare funding does not authorize anyone to require a doctor or nurse to perform or assist with an abortion against their religious beliefs or moral convictions.3Office of the Law Revision Counsel. 42 U.S. Code 300a-7 – Sterilization or Abortion With that protection in place, the conscience theory fell apart.
The second was economic injury: diverted resources, higher liability risk, increased malpractice premiums. The Court found the link between the FDA allowing other doctors to prescribe mifepristone under relaxed rules and these particular plaintiffs suffering financial losses “too speculative, lacks support in the record, and is otherwise too attenuated to establish standing.”2Supreme Court of the United States. Food and Drug Administration et al. v. Alliance for Hippocratic Medicine et al.
What Stays in Place
Because the case was thrown out on procedural grounds, every rule the plaintiffs attacked remains active. Nurse practitioners and physician assistants can prescribe mifepristone alongside physicians. The approved window runs through ten weeks of pregnancy — 70 days from the first day of the patient’s last menstrual period. The drug is taken as part of a two-pill regimen with misoprostol.4Food and Drug Administration. Questions and Answers on Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation Prescribers and pharmacies, including mail-order pharmacies, must be certified under the FDA’s Risk Evaluation and Mitigation Strategy program, and prescribers must review a Patient Agreement Form with each patient before writing the prescription.5Food and Drug Administration. Information About Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation Telehealth prescriptions and delivery by mail — the 2021 change that generated the most controversy — remain permitted.
Read this as a procedural off-ramp, not a substantive endorsement. The Supreme Court made no finding that the FDA’s decisions were scientifically sound, procedurally proper, or legally correct. It only found that these plaintiffs could not force the courts to answer.
The Comstock Act Question the Court Skipped
One of the more consequential arguments in the case involved the Comstock Act, an 1873 federal statute that declares any item “designed, adapted, or intended for producing abortion” nonmailable and prohibits sending such items through the postal service or common carrier.6Office of the Law Revision Counsel. 18 U.S. Code 1461 – Mailing Obscene or Crime-Inciting Matter Plaintiffs argued this dormant law should block the FDA from allowing mifepristone to be mailed. The Court’s standing dismissal meant it never ruled on the question.
The current federal interpretation comes from a 2022 Office of Legal Counsel opinion. The DOJ concluded that the Comstock Act does not prohibit mailing mifepristone or misoprostol when the sender lacks intent for the drugs to be used unlawfully. Because the drugs can be lawfully used in every state for various purposes, the DOJ reasoned, simply mailing them does not by itself establish criminal intent.7U.S. Department of Justice. Office of Legal Counsel – Application of the Comstock Act to the Mailing of Prescription Drugs That Can Be Used for Abortions Whether that interpretation survives under the current administration is unresolved. As of mid-2026, no Comstock Act prosecution has been brought against a pharmacy or provider for mailing mifepristone, but the statute remains on the books and could be enforced differently.
The Lawsuit Still Working Through Court
After the June 2024 ruling, the original private plaintiffs dropped their claims. Missouri, Kansas, and Idaho, which had intervened in the case, did not. The litigation has been transferred to the Eastern District of Missouri under the caption State of Missouri et al. v. Food and Drug Administration et al., with those three states as the sole plaintiffs.
The states are raising many of the same arguments: that the FDA violated federal administrative law when it loosened mifepristone’s regulations, that the changes conflict with the Comstock Act, and that the agency exceeded its authority. The critical difference is standing. States may have an easier time demonstrating concrete injury than private doctors did — pointing to costs borne by state healthcare systems, impacts on state regulatory programs, or direct conflicts with state law.
As of May 2026, briefing is ongoing. The FDA and the drug manufacturers Danco Laboratories and GenBioPro have filed motions to dismiss, and the states responded in late March 2026. If the court denies those motions, the case could proceed to a full trial on the merits — the ruling the Supreme Court never delivered.
Who Could Bring a Successful Challenge
The 2024 opinion effectively mapped out who cannot sue the FDA over mifepristone, and by implication who might. Doctors who do not prescribe the drug are out. Organizations that oppose it on ideological grounds are out; an organization cannot spend money advocating against a policy and then claim that spending as its injury.2Supreme Court of the United States. Food and Drug Administration et al. v. Alliance for Hippocratic Medicine et al.
The plaintiffs with the strongest claim to viable standing are states (already suing), patients who can show direct harm from the drug under the current framework, and regulated entities like pharmacies or prescribers caught between federal approval and state law. The Court said challenging the government’s regulation of someone else is “ordinarily substantially more difficult” than challenging regulation that applies directly to you.2Supreme Court of the United States. Food and Drug Administration et al. v. Alliance for Hippocratic Medicine et al. A future challenger will need to show a direct, personal stake, not a downstream worry about what could happen to someone else’s patients.
Where This Sits in the Wider Legal Fight
The mifepristone case sits inside the broader legal upheaval that followed Dobbs v. Jackson Women’s Health Organization, the 2022 decision that overturned Roe v. Wade and returned abortion regulation to state legislatures.8Supreme Court of the United States. Dobbs v. Jackson Women’s Health Organization Thirteen states have since enacted near-total abortion bans, and dozens more have set gestational limits. In states with bans, medication abortion by mail has become both a primary access route and a primary enforcement target.
The tension between federal drug approval and state criminal law remains unresolved. The FDA approved mifepristone for nationwide use, but states with bans treat prescribing or dispensing it as a crime. Whether federal approval preempts those state restrictions is a question no binding court ruling has answered for mifepristone. At least eight states have enacted shield laws protecting doctors and pharmacists who prescribe or mail abortion medication via telehealth to patients in ban states, and attorneys general in ban states are pursuing strategies designed to challenge those shield laws. The 2024 Supreme Court decision left every one of these fights standing.